Korean Circulation Journal

  • 제41권8호
  • /
  • Pages.458-463
  • /
  • 2011
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention

  • Yun, Kyeong-Ho (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Shin, Ik-Sang (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Shin, Seoung-Nam (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Choi, Jun-Ho (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Kim, Seung-Hwan (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Rhee, Sang-Jae (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Lee, Eun-Mi (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Yoo, Nam-Jin (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Kim, Nam-Ho (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Oh, Seok-Kyu (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Jeong, Jin-Won (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital)
  • 발행 : 2011.08.30
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: Statin therapy after percutaneous coronary intervention (PCI) has been associated with reduced major adverse cardiovascular events (MACE). However, it has been less clear as to whether statin therapy before acute coronary syndrome (ACS) is beneficial. We studied the effect of previous statin therapy, initiated ${\geq}$1 month before PCI, on the outcome of patients with ACS who had undergone early invasive strategies. Subjects and Methods: We stratified 479 consecutive patients with ACS who had undergone PCI, according to preprocedural statin administration as follows: previous statin-treated patients (statin group, n=237) and statin-naive patients (control group, n=242). The incidence of periprocedural myocardial infarction (MI) and in-hospital MACE was assessed. Results: The incidence of Braunwald class III angina and MI presentation were significantly lower in the statin group than in the control group. Angiographic and procedural characteristics were similar between the two groups; however, slow/no reflow phenomenon occurred more frequently in the control group. After PCI, the incidence of periprocedural MI was higher in the control group than in the statin group (6.6% vs. 2.1%, p=0.016). Multivariate analysis revealed that no prior use of statin {odds ratio (OR)=2.8; 95% confidence interval (CI)= 1.1-7.2; p=0.038), procedural complication (OR=4.0; 95% CI=1.5-10.5; p=0.004), stent overlap (OR=4.7; 95% CI=1.3-16.4; p=0.015), and old age (OR=3.2; 95% CI=1.2-8.0; p=0.016) were independent predictors for in-hospital MACE. Conclusion: Previous statin therapy before ACS was associated with milder clinical presentation and lower incidence of in-hospital MACE after early invasive strategies. The beneficial outcome is attributable to a significant reduction in periprocedural MI after PCI.

키워드

참고문헌

  1. Sacandinavian Simvastatin Survival Study (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
  2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7. https://doi.org/10.1056/NEJM199511163332001
  3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9. https://doi.org/10.1056/NEJM199610033351401
  4. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients of coronary heart disease and a board range of initial cholesterol levels. N Engl J Med 1998;339:1349-57. https://doi.org/10.1056/NEJM199811053391902
  5. Hong YJ, Jeong MH, Lim JH, et al. The prognostic significance of statin therapy according to the level of C-reactive protein in acute myocardial infarction patients who underwent percutaneous coronary intervention. Korean Circ J 2003;33:891-900.
  6. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82. https://doi.org/10.1016/S0140-6736(09)60447-5
  7. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvasta-tin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285: 1711-8. https://doi.org/10.1001/jama.285.13.1711
  8. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46:1405-10. https://doi.org/10.1016/j.jacc.2005.03.077
  9. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8. https://doi.org/10.1016/j.jacc.2007.02.025
  10. Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009;137:246-51. https://doi.org/10.1016/j.ijcard.2008.06.055
  11. Ishii H, Ichimiya S, Kanashiro M, et al. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther 2006;28:1812-9. https://doi.org/10.1016/j.clinthera.2006.11.003
  12. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-7. https://doi.org/10.1002/ccd.20078
  13. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin th-erapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Da-mage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54:558-65. https://doi.org/10.1016/j.jacc.2009.05.028
  14. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocar-dial infarction. Eur Heart J 2004;25:1822-8. https://doi.org/10.1016/j.ehj.2004.07.017
  15. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-6. https://doi.org/10.1161/01.CIR.0000060541.18923.E9
  16. Ebrahimi R, Saleh J, Toggart E, et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol 2008;20:292-5.
  17. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004;140:857-66. https://doi.org/10.7326/0003-4819-140-11-200406010-00006
  18. Bauer T, Bohm M, Zahn R, et al. Effect of chronic statin pretreatment on hospital outcome in patients with acute non-ST-elevation myocardial infarction. J Cardiovasc Pharmacol 2009;53:132-6. https://doi.org/10.1097/FJC.0b013e3181976a3c
  19. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9. https://doi.org/10.1161/hq1101.098486
  20. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:1524-34. https://doi.org/10.1161/01.ATV.0000032033.39301.6A
  21. Rhee SJ, Yun KH, Oh SK, et al. Changes of C-reactive protein are associated with myocardial injury after successful percutaneous coronary intervention. Korean Circ J 2008;38:135-9. https://doi.org/10.4070/kcj.2008.38.3.135
  22. Choi SY, Yang HM, Tahk SJ, et al. Preprocedural hs-CRP level serves as a marker for procedure-related myocardial injury during coronary stenting. Korean Circ J 2005;35:140-8. https://doi.org/10.4070/kcj.2005.35.2.140
  23. Yun KH, Jeong MH, Oh SK, et al. Response of high-sensitivity C-reactive protein to percutaneous coronary intervention in patients with acute coronary syndrome. Heart Vessels 2009;24:175-80. https://doi.org/10.1007/s00380-008-1110-5

피인용 문헌

  1. Current Statin Usage for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Multicenter Survey in Korea vol.35, pp.11, 2012, https://doi.org/10.1002/clc.22038
  2. Impact of Statin Use Before the Onset of Acute Myocardial Infarction on Coronary Plaque Morphology of the Culprit Lesion vol.64, pp.5, 2011, https://doi.org/10.1177/0003319712449196
  3. Reduced Left Ventricular Ejection Fraction Is a Risk Factor for In-Hospital Mortality in Patients after Percutaneous Coronary Intervention: A Hospital-Based Survey vol.2018, pp.None, 2011, https://doi.org/10.1155/2018/8753176
  4. Statin therapy in patients with high and very high cardiovascular risk: an optimal approach vol.19, pp.5, 2011, https://doi.org/10.15829//1728-8800-2020-2696